Olaparib and abiraterone for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well the combination of two drugs, olaparib and abiraterone, works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if this treatment helps patients live longer and feel better in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- Your prostate cancer must have spread to other parts of the body and keep growing even when testosterone is very low (castration-resistant).
- You must have been treated with a next-generation hormonal agent (like enzalutamide or apalutamide) before.
- You must be currently taking or planning to start olaparib plus abiraterone as your first treatment for castration-resistant cancer.
- You cannot have taken a PARP inhibitor before, and you cannot have taken abiraterone in the earlier hormone-sensitive stage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests a new investigational medicine (TY-302) combined with abiraterone, a standard hormone-blocking drug, in men with metastatic castration-resistant prostate cancer. It aims to see if this combination can slow cancer growth after initial hormone therapy stops working.
This trial is testing a new combination therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. The goal is to see if this treatment can shrink tumors or slow down the cancer, and it may offer a new option when standard treatments have not worked.
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
This trial tests combining three treatments—a targeted radiation drug (177Lu-PSMA), a PARP inhibitor (olaparib), and an immunotherapy (pembrolizumab)—for men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink tumors and slow cancer growth.
This expanded access program provides the experimental drug talazoparib (given in combination with enzalutamide) to patients with newly diagnosed metastatic prostate cancer that has become castrate-resistant (no longer responding to hormone therapy). The goal is to make this treatment available before it is formally approved.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.